Flu vaccines pass €1 billion in Sanofi-Aventis's Q4
This article was originally published in Scrip
Sanofi-Aventis has reported a 10% increase in its fourth-quarter net income as sales of its influenza vaccines grew to almost €1.1 billion. The French firm's human vaccines business expanded by 65% in the quarter, pushing group net income to €1.8 billion. More to follow.
You may also be interested in...
Perrigo’s clinical trials on CBD likely will take years before resulting products help bring order to the market. During earnings presentation, CEO Murray Kessler says the trials aren’t intended to establish claims for CBD but are more a long-term effort to provide data to FDA.
As draft guidance receives OMB review, FDA’s determination of no economic significance reflects its official position that the thousands of supplements, food and personal care products containing CBDs available in the US are unlawful.
AdvaMed Accell executive director Ashley Wittorf spoke in support of a proposed US House bill that would give financial help to small companies making products to address COVID-19.